Hepatitis B News and Research

Latest Hepatitis B News and Research

BRICS health ministers agree to improve access to low-cost medicines

Health ministers from Brazil, Russia, India, China, and South Africa in Beijing "on Monday vowed to improve access to low-cost and high-quality medicine - and called on developed nations to shoulder responsibility in helping the poor," Agence France-Presse reports.

13 Jul 2011

Sequana Medical's ALFApump System for liver cirrhosis receives CE Mark approval

Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System.

13 Jul 2011

Gilead, Mylan expand license deal for HIV/AIDS medicines

Mylan Inc. today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan's Matrix Laboratories Limited.

12 Jul 2011

Gilead announces expansion of global access program for HIV medications

Gilead Sciences, Inc. announced today an expansion of its global access program in an effort to provide accelerated access to Gilead medicines for the treatment of HIV/AIDS.

12 Jul 2011

Tips for preventing foodborne illness at home or while eating out

Dr. Melvin Pascall, an associate professor in the Department of Food Science and Technology at The Ohio State University, has spent the past 15 years working to improve food safety in areas ranging from packaging to food service cleaning practices.

11 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Inhibiting heat shock transcription factor 1 prevents liver cancer in mice

Altering the body's metabolism could be an effective treatment for deadly liver cancer, researchers report.

7 Jul 2011

European joint project to develop novel HCV vaccine based on nanotechnology

HCVAX is a European joint project that reaches out to develop a vaccine against hepatitis C based on nanotechnology. The German Helmholtz Centre for Infection Research in Braunschweig and its department "Vaccinology and Applied Microbiology" is now a part of the transnational consortium with researchers from Germany, France and Switzerland.

2 Jul 2011

UAB receives $31.7M award for Adolescent Medicine Trials Network for HIV/AIDS Interventions

The University of Alabama at Birmingham has received a five-year, $31.7 million award for its Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN), formed in 2001 to respond to the HIV epidemic in youth.

1 Jul 2011

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

A powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), holds great potential in the fight against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

30 Jun 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Accelerated hepatitis B vaccination schedule effective for high-risk pregnant women

UT Southwestern Medical Center maternal-fetal specialists have confirmed a potential new protocol to protect pregnant women who are at risk for hepatitis B, a health problem that affects 2 billion people worldwide.

28 Jun 2011

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

The Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, today said a clinical trial had shown that some strains of the bacteria (Helicobacter pylori or H. pylori) were safe and well tolerated in humans.

27 Jun 2011

Incivek-combination therapy increases chances of HCV patients achieving viral cure

The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That's the finding of a study published in the June 23rd issue of the New England Journal of Medicine.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

Nontoxic gold nanoparticles could detect growth of early tumors in liver

Hepatocellular carcinoma is the most common cancer to strike the liver. More than 500,000 people worldwide, concentrated in sub-Saharan Africa and Southeast Asia, are diagnosed with it yearly. Most of those afflicted die within six months.

23 Jun 2011

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset, Inc. announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 titled "Nucleoside Phosphoramidate Prodrugs".

22 Jun 2011

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.

22 Jun 2011

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Researchers from Boston University School of Medicine (BUSM) have found that among HIV-infected adults with alcohol problems, measuring their carbohydrate-deficient transferrin (CDT) biomarker was a poor and inaccurate method for detecting unhealthy drinking.

21 Jun 2011